Gadobutrol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gadobutrol
Gadobutrol skeletal.svg
Systematic (IUPAC) name
gadolinium(III) 2,2',2''-(10-((2R,3S)-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
Clinical data
AHFS/Drugs.com International Drug Names
Licence data US FDA:link
Pregnancy
category
  • US: C (Risk not ruled out)
Legal status
Routes of
administration
IV
Identifiers
CAS Registry Number 138071-82-6 YesY
ATC code V08CA09
PubChem CID: 72057
DrugBank DB06703 YesY
UNII 1BJ477IO2L YesY
KEGG D07420 YesY
ChEBI CHEBI:68841 N
ChEMBL CHEMBL1628503 N
Chemical data
Formula C18H31GdN4O9
Molecular mass 604.710 g/mol
 N (what is this?)  (verify)

Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).

It received marketing approval in Canada[1] and in the United States.[2][3][4]

As of 2007, it was the only GBCA approved at 1.0 molar concentrations.[5]

Gadobutrol is marketed by Bayer Schering Pharma as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.[6]

References[edit]

  1. ^ Cheng, KT (2007). Gadobutrol (PDF). Molecular Imaging and Contrast Agent Database (MICAD) (Bethesda, MD: National Center for Biotechnology Information (NCBI)). PMID 20641787. NBK23589. 
  2. ^ "Bayer in Radiology - Gadavist® (gadobutrol) injection 1 mmol/mL". bayerimaging.com. Retrieved 20 May 2015. 
  3. ^ "FDA approves imaging agent for central nervous system scans" (Press release). U.S. Food and Drug Administration (FDA). March 15, 2011. Retrieved March 31, 2011. 
  4. ^ "U.S. FDA Approves Bayer’s Gadavist (Gadobutrol) Injection for MRI of the Central Nervous System" (Press release). Bayer HealthCare Pharmaceuticals. March 14, 2011. Retrieved March 31, 2011. 
  5. ^ "Education for Cardiology Disease Professionals - Radcliffecardiology" (PDF). touchcardiology.com. Retrieved 20 May 2015. 
  6. ^ "Gadavist full prescribing information" (PDF). Retrieved 2011-03-14.